ALR Technologies announced the FDA granted clearance for an innovative insulin dose adjustment feature of the ALRT diabetes management system.
ALR Technologies (OTCQB:ALRT) announced the US Food and Drug Administration (FDA) granted clearance for an innovative insulin dose adjustment (IDA) feature of the ALRT diabetes management system.
As quoted in the press release:
The ALRT system with IDA uses the American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) insulin dosing guidelines to process patient blood glucose values to provide reference doses based on the guidelines. The reference doses are compared with the patient’s current insulin dose(s) to determine whether current insulin dosing is optimal. If there is a difference between the patient’s current insulin dose(s) and the reference doses, this difference will be flagged and a notification sent to the managing healthcare provider (HCP) suggesting an insulin dose review. The blood glucose values are uploaded directly from the patient’s blood glucose meter.